Dr Charles Merritt Beasley, Jr.

All Stories

1. Article

   Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods
   Dr Charles Merritt Beasley, Jr.
2. Article

   Twenty-Four–Hour Measures of Heart Rate–Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment
   Dr Charles Merritt Beasley, Jr.
3. Article

   Reference Limits for Outlier Analyses in Randomized Clinical Trials
   Dr Charles Merritt Beasley, Jr.
4. Article

   Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
   Dr Charles Merritt Beasley, Jr.
5. Article

   Systematic Decrements in QTc between the First and Second Day of Contiguous Daily ECG Recordings under Controlled Conditions
   Dr Charles Merritt Beasley, Jr.
6. Article

   Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development
   Dr Charles Merritt Beasley, Jr.
7. Article

   Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development
   Dr Charles Merritt Beasley, Jr.
8. Article

   Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials
   Dr Charles Merritt Beasley, Jr.
9. Article

   Letter to the Editor
   Dr Charles Merritt Beasley, Jr.
10. Article

    Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
    Dr Charles Merritt Beasley, Jr.
11. Article

    Fluoxetine and Adult Suicidality Revisited
    Dr Charles Merritt Beasley, Jr.
12. Article

    Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder
    Dr Charles Merritt Beasley, Jr.
13. Article

    All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics
    Dr Charles Merritt Beasley, Jr.
14. Article

    Early Symptomatic Worsening During Treatment With Fluoxetine in Major Depressive Disorder
    Dr Charles Merritt Beasley, Jr.
15. Article

    Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes
    Dr Charles Merritt Beasley, Jr.
16. Article

    Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis
    Dr Sean EkinsDr Charles Merritt Beasley, Jr.
17. Article

    Is Quality of Life Among Minimally Symptomatic Patients With Schizophrenia Better Following Withdrawal or Continuation of Antipsychotic Treatment?
    Dr Charles Merritt Beasley, Jr.
18. Article

    Efficacy and Safety of Oral Tadalafil in the Treatment of Men in Canada with Erectile Dysfunction: A Randomized, Double‐Blind, Parallel, Placebo‐Controlled Clinical Trial
    Dr Charles Merritt Beasley, Jr.
19. Article

    The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval
    Dr Charles Merritt Beasley, Jr.
20. Article

    Tadalafil Improved Erectile Function at Twenty-Four and Thirty-Six Hours After Dosing in Men With Erectile Dysfunction: US Trial
    Dr Charles Merritt Beasley, Jr.
21. Article

    Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5—sildenafil, tadalafil, and vardenafil
    Dr Charles Merritt Beasley, Jr.
22. Article

    A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil
    Dr Charles Merritt Beasley, Jr.
23. Article

    A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse
    Dr Charles Merritt Beasley, Jr.
24. Article

    Tadalafil has No Detrimental Effect on Human Spermatogenesis or Reproductive Hormones
    Dr Charles Merritt Beasley, Jr.
25. Article

    An Integrated Analysis of Acute Treatment-Emergent Extrapyramidal Syndrome in Patients With Schizophrenia During Olanzapine Clinical Trials
    Dr Charles Merritt Beasley, Jr.
26. Article

    Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients
    Dr Charles Merritt Beasley, Jr.
27. Article

    When Should a Trial of Fluoxetine for Major Depression Be Declared Failed?
    Dr Charles Merritt Beasley, Jr.
28. Article

    Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol
    Dr Charles Merritt Beasley, Jr.
29. Article

    Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo
    Dr Charles Merritt Beasley, Jr.
30. Article

    Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia
    Dr Charles Merritt Beasley, Jr.
31. Article

    Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment
    Dr Charles Merritt Beasley, Jr.
32. Article

    Fluoxetine and Norfluoxetine Plasma Levels After Discontinuing Fluoxetine Therapy
    Dr Charles Merritt Beasley, Jr.
33. Article

    Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis
    Dr Charles Merritt Beasley, Jr.
34. Article

    Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial
    Dr Charles Merritt Beasley, Jr.
35. Article

    Hematologic Reference Ranges in a Population of Patients with Schizophrenia
    Dr Charles Merritt Beasley, Jr.
36. Article

    Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis
    Dr Charles Merritt Beasley, Jr.
37. Article

    Efficacy, Adverse Events, and Treatment Discontinuations in Fluoxetine Clinical Studies of Major Depression
    Dr Charles Merritt Beasley, Jr.
38. Article

    Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression
    Dr Charles Merritt Beasley, Jr.
39. Article

    Fluoxetine efficacy in menopausal women with and without estrogen replacement
    Dr Charles Merritt Beasley, Jr.
40. Article

    Plasma Olanzapine and Clinical Response
    Dr Charles Merritt Beasley, Jr.
41. Article

    Blood Pressure Changes During Short-Term Fluoxetine Treatment
    Dr Charles Merritt Beasley, Jr.
42. Article

    Response to Letter of Professor Tim Lambert
    Dr Charles Merritt Beasley, Jr.
43. Article

    Olanzapine
    Dr Charles Merritt Beasley, Jr.
44. Article
    Dr Charles Merritt Beasley, Jr.
45. Article

    Olanzapine versus haloperidol in the treatment of schizoaffective disorder
    Dr Charles Merritt Beasley, Jr.
46. Article

    Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
    Dr Charles Merritt Beasley, Jr.
47. Article

    Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
    Dr Charles Merritt Beasley, Jr.
48. Article

    Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode
    Dr Charles Merritt Beasley, Jr.
49. Article

    Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment
    Dr Charles Merritt Beasley, Jr.
50. Article

    A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia
    Dr Charles Merritt Beasley, Jr.
51. Article

    Safety of Abrupt Discontinuation of Fluoxetine
    Dr Charles Merritt Beasley, Jr.
52. Article

    Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
    Dr Charles Merritt Beasley, Jr.
53. Article

    Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo
    Dr Charles Merritt Beasley, Jr.
54. Article

    Olanzapine Versus Placebo and Haloperidol: Quality of Life and Efficacy Results of the North American Double-Blind Trial
    Dr Charles Merritt Beasley, Jr.
55. Article

    Suicidality with Fluoxetine
    Dr Charles Merritt Beasley, Jr.
56. Article

    Olanzapine Plasma Concentrations and Clinical Response in Acutely Ill Schizophrenic Patients
    Dr Charles Merritt Beasley, Jr.
57. Article

    Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia
    Dr Charles Merritt Beasley, Jr.
58. Article

    Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders
    Dr Charles Merritt Beasley, Jr.
59. Article

    Fluoxetine in Medically Stable, Depressed Geriatric Patients
    Dr Charles Merritt Beasley, Jr.
60. Article

    Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
    Dr Charles Merritt Beasley, Jr.
61. Article

    The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
    Dr Charles Merritt Beasley, Jr.
62. Article

    Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study
    Dr Charles Merritt Beasley, Jr.
63. Article

    Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia
    Dr Charles Merritt Beasley, Jr.
64. Article

    Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
    Dr Charles Merritt Beasley, Jr.
65. Article

    Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
    Dr Charles Merritt Beasley, Jr.
66. Article

    Fluoxetine in Depressed Patients on Dialysis
    Dr Charles Merritt Beasley, Jr.
67. Article

    Letter to the editors
    Dr Charles Merritt Beasley, Jr.
68. Article

    Olanzapine VS. chlorpromazine in therapy-refractory schizophrenia
    Dr Charles Merritt Beasley, Jr.
69. Article

    Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
    Dr Charles Merritt Beasley, Jr.
70. Article

    Olanzapine versus Placebo and Haloperidol
    Dr Charles Merritt Beasley, Jr.
71. Article

    Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function
    Dr Charles Merritt Beasley, Jr.
72. Article

    Absence of a Relationship Between Adverse Events and Suicidality During Pharmacotherapy for Depression
    Dr Charles Merritt Beasley, Jr.
73. Article

    Fluoxetine
    Dr Charles Merritt Beasley, Jr.
74. Article

    Fluoxetine not associated with increased aggression in controlled clinical trials
    Dr Charles Merritt Beasley, Jr.
75. Article

    Fluoxetine versus amitriptyline in the treatment of major depression
    Dr Charles Merritt Beasley, Jr.
76. Article

    The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine
    Dr Charles Merritt Beasley, Jr.
77. Article

    Fluoxetine
    Dr Charles Merritt Beasley, Jr.
78. Article

    Reply to Dr. Friedman
    Dr Charles Merritt Beasley, Jr.
79. Article

    Fluoxetine: a review of receptor and functional effects and their clinical implications
    Dr Charles Merritt Beasley, Jr.
80. Article

    Fluoxetine: no association with suicidality in obsessive-compulsive disorder
    Dr Charles Merritt Beasley, Jr.
81. Article

    Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
    Dr Charles Merritt Beasley, Jr.
82. Article

    Fluoxetine Mechanism of Action
    Dr Charles Merritt Beasley, Jr.
83. Article

    High-Dose Fluoxetine
    Dr Charles Merritt Beasley, Jr.
84. Article

    Fluoxetine in tricyclic refractory major depressive disorder
    Dr Charles Merritt Beasley, Jr.
85. Article

    Correction to ‘Fluoxetine Overdose: A Case Report’
    Dr Charles Merritt Beasley, Jr.
86. Article

    TSH response to TRH and haloperidol response latency in psychoses
    Dr Charles Merritt Beasley, Jr.
87. Article

    A General Learning Theory and its Application to Schema Abstraction1
    Dr Charles Merritt Beasley, Jr.